CLX

Business profile & competitive position

The Clorox Company is a multinational manufacturer and marketer of consumer and professional products, classified in the Consumer Defensive sector and the Household & Personal Products industry. Its fiscal 2026 net sales reached $6.7 billion, generated by roughly 9,200 employees operating in approximately 25 countries and selling in about 95 markets. The consumer brand lineup includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt's Bees; on the professional side, products are sold under Purell, CloroxPro, and Clorox Healthcare.

The company's 8.7% net margin is the cleanest read on current profitability in the provided data. That margin suggests a business that can convert a meaningful portion of each revenue dollar into earnings, consistent with the pricing power that comes from decades-old household names. However, the reported return on equity of -1,893.5% is not a useful moat signal here. A figure that extreme usually reflects a negative shareholders' equity base—often the result of long-term share buybacks and debt-funded capital returns—rather than disastrous operations. In that context, ROE loses meaning and investors instead look to margins, cash flow, and brand resilience.

Customer concentration is a genuine constraint on bargaining power. Walmart alone accounted for 26% of consolidated fiscal 2026 net sales, and the five largest customers represented roughly half. That gives large retailers significant leverage on pricing and shelf space, offsetting some of the advantage Clorox gets from brand recognition.

Financial posture

Clorox currently carries an $11.3 billion market capitalization and trades at a 19.3 P/E ratio, implying an earnings yield of roughly 5.2%. That multiple sits within a range often associated with mature, moderate-growth consumer staples, neither deep-value nor premium. The stock is at $93.06, with a 30.1 RSI and a 50-day exponential moving average of $100.14, meaning the price has slipped below its medium-term trend and the momentum indicator is near oversold territory.

Profitability is anchored by the 8.7% net margin, while the beta of 0.54 indicates materially lower volatility than the broader market. The -1,893.5% ROE should be viewed as a balance-sheet artifact rather than an operating return metric. Notably, the company has been active on the capital-allocation front: in April 2026 it completed the GOJO Industries acquisition, expanding its health and hygiene exposure, and on January 31, 2026 the Glad bags and wraps venture with P&G expired, requiring Clorox to purchase P&G's 20% interest.

Strategic priorities & outlook

Clorox's most recent 10-K outlines an operational agenda centered on the IGNITE strategy. The company has four explicit choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Beneath that umbrella sits a major enterprise resource planning (ERP) rollout and broader digital transformation intended to drive long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The company also plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to become more resilient and to deliver more consistent profitable growth. Health and hygiene expansion is a specific priority, including integrating the GOJO acquisition and growing professional and institutional markets.

The filing was candid about fiscal 2026 weakness: organic sales and earnings both declined, with diluted EPS down 26%, partly due to macroeconomic headwinds and the timing of ERP-related sales that had been pulled into fiscal 2025. Those headwinds, combined with the customer concentration described above, illustrate why near-term execution matters as much as brand strength.

Macro & geopolitical exposure

As a Household & Personal Products company with global reach, Clorox is exposed to several macro channels. Input costs for cleaning, bags, wraps, charcoal, and personal-care products move with commodity-linked raw materials such as resins, plastics, pulp, chemicals, and energy. Transportation and logistics costs also flow directly into margins. Because roughly 95 markets are involved, currency translation can swing reported revenues and earnings from one period to the next.

The sector also sits in the path of trade policy. Tariffs on imported raw materials or finished goods, packaging components, and manufacturing equipment can pressure costs, while regulatory changes around chemical safety, labeling, and environmental standards can affect formulation and compliance expenses. Inflation and consumer trade-down behavior can influence volume and mix, particularly when private-label alternatives gain shelf space. Finally, the professional products business is exposed to institutional demand cycles, including healthcare utilization and commercial occupancy trends.

Recent developments

Recent headlines have focused on margins, valuation, and sentiment. On September 3, 2026, Zacks asked whether cost savings could offset inflation and protect Clorox's margins, signaling that margin compression is the central debate heading into the next quarterly cycle. A day earlier, on September 2, 2026, Zacks noted that the stock had fallen 9.3% since the last earnings report and questioned whether a rebound was in store. On September 1, 2026, Zacks compared Clorox with Ahold Delhaize (ADRNY) on a value basis. Separately, on August 31, 2026, defenseworld.net reported that the Canada Pension Plan Investment Board acquired 32,488 shares of CLX.

That institutional buying stood in contrast to the weak price action. At $93.06, the stock has slipped below its 50-day EMA of $100.14, and the RSI at 30.1 is flirting with oversold levels. The juxtaposition of new institutional interest and a 9.3% post-earnings decline captures the debate: bulls point to defensive cash flows and cost-saving potential, while bears point to volume pressure and near-term margin risk.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten the Street's official estimate six times, a 75% beat rate, with an average earnings surprise of 9.6%. In the five trading days following each report, the stock has averaged a 1.67% gain, classified as an upward post-earnings drift.

The underlying prints tell a more nuanced story. The most recent quarter, reported August 3, 2026, delivered $1.66 versus a $1.64 estimate—a 1.2% beat—and the stock rose 6.52% the next day and 9.61% over the following five days. Yet the prior quarter, April 30, 2026, showed a larger 5.8% beat ($1.64 versus $1.55) and was punished with a 9.67% one-day drop and a 4.49% five-day decline. In the February 3, 2026 quarter, Clorox missed by 2.8% ($1.39 versus $1.43) and still rallied 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter, a 3.9% beat, produced a 1.17% next-day gain but a 4.08% five-day loss.

The pattern suggests that the market's real expectation can differ materially from the reported consensus, and that guidance, margin trajectory, and the ERP/GOJO narrative have driven post-earnings price action more than the headline EPS beat or miss. The next scheduled report is November 3, 2026, after the close, with a consensus EPS estimate of $1.11.

For a deeper dive into how institutional analysts are interpreting Clorox's November 3 earnings setup and the broader household-products outlook, consult the full institutional verdict.